Guardant Health announced the formation of the Single Namespace Working Group (SNS) on November 12 2025. The consortium, comprising 34 technology, healthcare, and research institutions, has drafted the first open standard for exabyte‑scale data interoperability, aiming to unify distributed data across storage providers into a single seamless namespace.
The SNS standard will streamline secure data accessibility, migration, and collaboration across platforms. By providing a common framework, the group seeks to reduce fragmentation and operational costs for large‑scale genomic and clinical datasets, directly benefiting Guardant’s Infinity Smart Liquid Biopsy platform and its multi‑omic data analytics pipeline.
Founding members include NetApp, Seagate, IBM, DDN, Genentech, Hammerspace, Weka, and Lawrence Livermore National Laboratory. The consortium has been collaborating for 18 months, and the draft specifications are expected in early 2026, with formal publication by the OASIS standards body later that year.
Public discussions are scheduled for the Supercomputing 2025 conference in St. Louis (November 16‑21 2025), where the group will present its progress and transition the specifications to OASIS.
For Guardant, the new standard enhances AI‑ready infrastructure, enabling faster data integration and model training for the Infinity platform. The unified namespace reduces data silos, lowers migration costs, and strengthens Guardant’s data moat, positioning the company to pursue new partnerships and revenue opportunities in precision oncology.
Helmy Eltoukhy, Guardant’s chairman and co‑CEO, said the initiative “accelerates insights, collaboration, and innovation by making data available everywhere.” Chief Information Officer Kumud Kalia added that the standard “shifts focus from data management to faster data insights, translating into better patient care.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.